Compare SOMN & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOMN | WGSWW |
|---|---|---|
| Founded | 1946 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Metal Mining | Retail: Computer Software & Peripheral Equipment |
| Sector | Basic Materials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | SOMN | WGSWW |
|---|---|---|
| Price | $53.26 | $0.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 250.3K | 61.3K |
| Earning Date | 01-01-0001 | 02-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $305,450,000.00 |
| Revenue This Year | $8.18 | N/A |
| Revenue Next Year | $5.61 | N/A |
| P/E Ratio | $22.48 | ★ N/A |
| Revenue Growth | N/A | ★ 50.79 |
| 52 Week Low | $47.87 | $0.01 |
| 52 Week High | $53.99 | $0.29 |
| Indicator | SOMN | WGSWW |
|---|---|---|
| Relative Strength Index (RSI) | 58.40 | 34.65 |
| Support Level | $49.35 | $0.01 |
| Resistance Level | $53.99 | $0.02 |
| Average True Range (ATR) | 0.57 | 0.00 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 44.22 | 10.48 |
Southern is one of the largest utilities in the US. The company serves 9 million customers with vertically integrated electric utilities in three states and natural gas distribution utilities in four states. It owns 44 gigawatts of rate-regulated generating capacity, primarily for serving customers in Georgia, Alabama, and Mississippi. Subsidiary Southern Power owns 13 gigawatts of natural gas generation and renewable energy across the US and sells the electricity primarily under long-term contracts.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.